- Home
- IMNN vs LYRA Comparison
IMNN vs LYRA Comparison
Compare IMNN & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNN
- LYRA
- Stock Information
- Founded
- IMNN 1982
- LYRA 2005
- Country
- IMNN United States
- LYRA United States
- Employees
- IMNN N/A
- LYRA N/A
- Industry
- IMNN Biotechnology: Pharmaceutical Preparations
- LYRA Medical/Dental Instruments
- Sector
- IMNN Health Care
- LYRA Health Care
- Exchange
- IMNN Nasdaq
- LYRA Nasdaq
- Market Cap
- IMNN 12.1M
- LYRA 11.6M
- IPO Year
- IMNN 1985
- LYRA 2020
- Fundamental
- Price
- IMNN $6.53
- LYRA $7.47
- Analyst Decision
- IMNN Buy
- LYRA Hold
- Analyst Count
- IMNN 2
- LYRA 1
- Target Price
- IMNN $182.61
- LYRA $16.00
- AVG Volume (30 Days)
- IMNN 244.8K
- LYRA 21.5K
- Earning Date
- IMNN 08-05-2025
- LYRA 08-12-2025
- Dividend Yield
- IMNN N/A
- LYRA N/A
- EPS Growth
- IMNN N/A
- LYRA N/A
- EPS
- IMNN N/A
- LYRA N/A
- Revenue
- IMNN N/A
- LYRA $770,000.00
- Revenue This Year
- IMNN N/A
- LYRA N/A
- Revenue Next Year
- IMNN N/A
- LYRA $139.18
- P/E Ratio
- IMNN N/A
- LYRA N/A
- Revenue Growth
- IMNN N/A
- LYRA N/A
- 52 Week Low
- IMNN $4.83
- LYRA $3.81
- 52 Week High
- IMNN $41.22
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- IMNN 40.89
- LYRA 48.46
- Support Level
- IMNN $6.17
- LYRA $6.92
- Resistance Level
- IMNN $7.21
- LYRA $7.57
- Average True Range (ATR)
- IMNN 0.51
- LYRA 0.46
- MACD
- IMNN 0.14
- LYRA 0.18
- Stochastic Oscillator
- IMNN 20.45
- LYRA 90.57
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.